Site Search
Professionals 830 results
Capabilities 91 results
Industry
Winston has been a major player in the life sciences industry for decades. We represent market-leading clients across this broad sector, including companies involved in pharmaceuticals, biologics, biosimilars, biotechnology, and medical devices. Our attorneys are seasoned practitioners—many of whom have technical degrees in areas key to the life sciences sector, including biology, chemistry, pharmacy, and biomedical engineering—and bring a unique understanding of the industry and perspective to our representations.
Industry
The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions.
Practice Area
Winston & Strawn’s private equity attorneys provide strategic advice and legal counsel to middle-market private equity funds, hedge funds, family offices, real estate funds, alternative asset managers, portfolio companies, and institutional investors. We have one of the broadest and most active national middle-market private equity practices in the U.S.
Experience 642 results
Experience
|January 29, 2026
A team led by Justin Levy, Austin Leach, and Ben Popeck served as sell-side advisors to GenNx360 Capital Partners in the sale of its portfolio company, Precision Aviation Group, to VSE Corporation for a total upfront consideration of approximately $2.025 billion in cash and equity. PAG expects to generate approximately $615 million of adjusted revenue for the fiscal year ended December 31, 2025. Together, VSE and PAG will create a more diversified, globally scaled aviation aftermarket platform with broader technical capabilities and an expanded portfolio of proprietary repair and solutions content designed to strengthen customer support, extend asset life, and reduce total cost of ownership.
Experience
|January 22, 2026
Advised SQM on US$600M offering of subordinated capital notes due 2056 (Hybrid Bond Offering)
Winston & Strawn LLP advised longstanding client Sociedad Química y Minera de Chile S.A. (“SQM”) (NYSE: SQM) on its US$600 million offering of subordinated capital notes. The notes were offered in the United States pursuant to Rule 144A and outside the United States pursuant to Regulation S.The subordinated capital notes are due in 2056 and constitute SQM’s first international hybrid bond issuance, structured to be consistent with SQM’s recent UF 10 million (approximately US$ 430 million) Series S hybrid-subordinated bond issuance in the Chilean securities market. The notes bear an initial annual interest rate of 5.625% and are subject to reset on April 22, 2031 (the “First Reset Date”), and on every fifth anniversary thereafter, based on a spread over the 5-year U.S. Treasury bond rate, with interest rate step-ups on the fifth and twentieth anniversaries of the First Reset Date. The transaction closed on January 22, 2026.BofA Securities, Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Santander US Capital Markets LLC, and Scotia Capital (USA) Inc. acted as initial purchasers of the notes.Link Capital Partners was financial advisor to SQM.SQM is a global company with a leading position in the lithium, iodine, and potassium nitrate markets. It develops and produces a diverse range of products for industries essential to human progress, including health, nutrition, renewable energy, and technology, driven by innovation and technological development.The Winston & Strawn team advising on the transaction included corporate partner Sey-Hyo Lee (New York) and foreign legal advisor Bruno M. Fiorino (New York). Partner Katherine Erbeznik (New York) advised on tax matters.
Experience
|January 21, 2026
Winston Represents Century Park Capital Partners In Its Exit of MCCi
Winston represented Century Park Capital Partners and its portfolio company MCCi, LLC, in connection with an investment by Incline Equity Partners in MCCi. MCCi is a provider of enterprise content management and workflow automation solutions to public sector clients with a comprehensive suite of products that enable state and local governments to solve manual workflow challenges and drive operational efficiency throughout their organizations. Under Century Park's stewardship, MCCi strengthened its position as a leader in business process automation while maintaining its culture of exceptional customer service.
Insights & News 6,692 results
Sponsorship
|February 3, 2026
Winston & Strawn is excited to participate in IPEM Cannes Wealth 2026, where we will host and attend premier events that bring together industry leaders for networking and collaboration.
Client Alert
|February 3, 2026
|5 Min Read
UK Crypto Regulation Moves Forward: Lending, Staking & DeFi - Key Takeaways from FCA CP25/40
The close of 2025 highlighted the continuing momentum for the digital asset industry, with regulatory developments accelerating rather than slowing. In December, the UK Government and the Financial Conduct Authority (FCA) released a series of draft instruments and consultation papers that are poised to play a significant role in shaping the sector’s future. On 15 December 2025, HM Treasury (HMT) published a revised draft of The Financial Services and Markets Act 2000 (Cryptoassets) Order 2025. This was followed on 16 December 2025 by the FCA’s publication of three consultation papers addressing core elements of the forthcoming cryptoasset regulatory framework: (1) CP25/40 Regulating Cryptoasset Activities, (2) CP25/41 Regulating Cryptoassets: Admissions & Disclosures and Market Abuse Regime for Cryptoassets, and (3) CP25/42 A Prudential Regime for Cryptoasset Firms. Momentum continued into the new year. On 8 January 2026, the FCA provided further detail on its proposed “gateway” the application process through which firms will seek authorisation to carry on newly regulated cryptoasset activities under the UK’s forthcoming regime.
Press Release
|February 2, 2026
|1 Min Read
Winston & Strawn Adds Partner David Love to Growing Leveraged Finance Team
Chicago – February 2, 2026 – Winston & Strawn LLP announced today the addition of David Love to the firm’s Chicago office. He joins the firm’s Transactions Department as a partner in the Finance Practice.
Other Results 130 results
Site Content
Site Content
Site Content